220 related articles for article (PubMed ID: 33932239)
1. High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients.
Nitta H; Younès A; El-Domiaty N; Karam V; Sobesky R; Vibert E; Coilly A; Maria Antonini T; De Martin E; Cherqui D; Baba H; Rosmorduc O; Adam R; Samuel D; Saliba F
Transpl Int; 2021 Jul; 34(7):1293-1305. PubMed ID: 33932239
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
4. Trough Levels of Everolimus Are Associated With Recurrence Rates of Hepatocellular Carcinoma After Liver Transplantation.
Cholongitas E; Antoniadis N; Goulis I; Theocharidou E; Ιmvrios G; Giouleme O; Filis D; Mouloudi E; Akriviadis E; Fouzas I
Transplant Proc; 2019 Mar; 51(2):450-453. PubMed ID: 30879564
[TBL] [Abstract][Full Text] [Related]
5. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
Li Z; Gao J; Zheng S; Wang Y; Xiang X; Cheng Q; Zhu J
Turk J Gastroenterol; 2021 Jan; 32(1):30-41. PubMed ID: 33893764
[TBL] [Abstract][Full Text] [Related]
7. The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Li BCW; Chiu J; Shing K; Kwok GGW; Tang V; Leung R; Ma KW; She WH; Tsang J; Chan A; Cheung TT; Lo CM; Yau T
Adv Ther; 2021 Jul; 38(7):3900-3910. PubMed ID: 34061324
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Kang SH; Cho H; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yi NJ; Lee KW; Suh KS; Yoon JH
J Korean Med Sci; 2018 Nov; 33(45):e283. PubMed ID: 30402048
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
11. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
15. Everolimus-based immunosuppression in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation: a case series.
Ferreiro AO; Vazquez-Millán MA; López FS; Gutiérrez MG; Diaz SP; Patiño MJ
Transplant Proc; 2014 Dec; 46(10):3496-501. PubMed ID: 25498079
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation.
Lee SK; Jang JW; Nam H; Sung PS; Kim HY; Kwon JH; Lee SW; Song DS; Kim CW; Song MJ; Choi HJ; You YK; Bae SH; Choi JY; Yoon SK
Hepatol Int; 2021 Feb; 15(1):137-145. PubMed ID: 33496932
[TBL] [Abstract][Full Text] [Related]
17. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Alsina AE; Makris A; Nenos V; Sucre E; Arrobas J; Franco E; Kemmer N
Am Surg; 2014 Jul; 80(7):680-4. PubMed ID: 24987900
[TBL] [Abstract][Full Text] [Related]
18. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive treatment with everolimus in patients after liver transplant: 4 years of single-center experience.
Wasilewicz MP; Moczydłowska D; Janik M; Grąt M; Zieniewicz K; Raszeja-Wyszomirska J
Pol Arch Intern Med; 2019 Oct; 129(10):686-691. PubMed ID: 31502586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]